Monday 16 November 2026
Export KYNB’s income statement to Excel — free account
Kyntra Bio Inc
KYNBKyntra Bio Inc’s revenue for fiscal 2025 (year ended December 2025) was $6.4 million, down 78.3% from fiscal 2024.
- Revenue
- n/m
- EPS
- n/m
- Free cash flow
- n/m
Quarter to June 2026, against a year earlier
3.44
0.15
−4.18%
Follow KYNB
Alert me
Revenue to profit Fiscal 2025, year to 31 December 2025
Of every $100 of revenue, $2848.63 was left as profit. What is an income statement?
| Revenue | 0.0 | 100.0% |
|---|---|---|
| Cost of revenue | 0.0 | −8.6% |
| Gross profit | 0.0 | 91.4% |
| Research & development | 0.0 | −365.2% |
| Selling, general & admin | 0.0 | −430.3% |
| Other operating costs | 0.0 | −8.6% |
| Operating income | 0.0 | −712.7% |
| Other income, net | 0.0 | −192.5% |
| Income tax | 0.0 | 1.4% |
| Other items | +0.2 | 3752.4% |
| Net income | 0.2 | 2848.6% |
| FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.2B | $0.1B | $0.2B | $0.3B | $0.2B | $0.2B | $0.1B | $0.0B | $0.0B | $0.0B |
| Operating income | −$0.1B | −$0.1B | −$0.1B | −$0.1B | −$0.2B | −$0.3B | −$0.3B | −$0.3B | −$0.2B | $0.0B |
| Net income | −$0.1B | −$0.1B | −$0.1B | −$0.1B | −$0.2B | −$0.3B | −$0.3B | −$0.3B | $0.0B | $0.2B |
| Net margin (right axis) | −31.7% | −92.3% | −40.6% | −30.0% | −107.4% | −123.3% | −208.7% | −607.3% | −160.6% | 2848.6% |
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Revenue |
183.19 | 131.00 | 212.96 | 256.58 | 176.32 | 235.31 | 140.73 | 46.80 | 29.62 | 6.44 |
Revenue Growth |
1.31% | (28.49%) | 62.57% | 20.48% | (31.28%) | 33.46% | (40.19%) | (66.74%) | (36.71%) | (78.26%) |
Cost of Revenue |
— | — | — | 1.15 | 8.87 | 12.87 | 20.28 | 3.96 | 15.56 | 0.56 |
Gross Profit |
183.19 | 131.00 | 212.96 | 255.43 | 167.45 | 222.44 | 120.45 | 42.84 | 14.06 | 5.88 |
R&D Expenses |
187.21 | 196.52 | 235.84 | 209.27 | 252.92 | 387.04 | 296.79 | 266.47 | 95.69 | 23.52 |
SG&A Expenses |
46.03 | 51.76 | 63.81 | 135.48 | 106.41 | 123.93 | 124.69 | 86.48 | 49.33 | 27.71 |
Operating Income |
(50.04) | (117.28) | (86.69) | (89.31) | (191.88) | (288.53) | (301.02) | (322.72) | (150.42) | (45.89) |
Non-operating Income/Expense |
(8.10) | (3.27) | 0.58 | 12.67 | 3.15 | (2.15) | 6.16 | (0.50) | (2.95) | (12.40) |
Non-operating Interest Expenses |
10.73 | 9.71 | 10.99 | 2.88 | 2.40 | 1.08 | 1.44 | 8.10 | 8.25 | 8.76 |
Investment Gain/Loss (Other) |
— | — | — | — | (0.20) | 1.01 | 1.57 | 2.64 | — | — |
| (58.14) | (120.55) | (86.12) | (76.64) | (188.73) | (290.68) | (294.87) | (323.22) | (153.37) | (58.29) | |
Income Tax Provision |
(0.07) | 0.32 | 0.30 | 0.33 | 0.36 | 0.35 | 0.36 | (0.25) | (0.27) | (0.09) |
Income after Tax |
(58.07) | (120.87) | (86.42) | (76.97) | (189.09) | (291.03) | (295.23) | (322.97) | (153.10) | (58.20) |
Net Income Common |
(58.07) | (120.87) | (86.42) | (76.97) | (189.29) | (290.02) | (293.65) | (284.23) | (47.58) | 183.45 |
EPS (Basic) |
(24.50) | (43.25) | (25.75) | (22.25) | (52.75) | (78.50) | (78.50) | (73.00) | (12.00) | 45.37 |
EPS (Diluted) |
(24.50) | (43.25) | (25.75) | (22.25) | (52.75) | (78.50) | (78.50) | (73.00) | (12.00) | 45.37 |
Shares (Basic, Weighted) |
2.51 | 2.92 | 3.36 | 3.47 | 3.59 | 3.69 | 3.74 | 3.89 | 4.00 | 4.04 |
Shares (Diluted, Weighted) |
2.51 | 2.92 | 3.36 | 3.47 | 3.59 | 3.69 | 3.74 | 3.89 | 4.00 | 4.04 |
Gross Margin |
100.00% | 100.00% | 100.00% | 99.55% | 94.97% | 94.53% | 85.59% | 91.53% | 47.47% | 91.37% |
EBIT Margin |
(27.32%) | (89.53%) | (40.71%) | (34.81%) | (108.83%) | (122.62%) | (213.90%) | (689.53%) | (507.80%) | (712.66%) |
EBT margin |
(31.74%) | (92.03%) | (40.44%) | (29.87%) | (107.04%) | (123.53%) | (209.52%) | (690.60%) | (517.76%) | (905.19%) |
Net Profit Margin |
(31.70%) | (92.27%) | (40.58%) | (30.00%) | (107.36%) | (123.25%) | (208.66%) | (607.29%) | (160.63%) | 2,848.63% |
Free Cash Flow Margin |
3.20% | (57.26%) | (39.44%) | (32.92%) | 44.02% | (47.77%) | (131.22%) | (678.46%) | (463.25%) | (74.72%) |
EBITDA |
(41.27) | (109.34) | (80.17) | (71.53) | (169.73) | (271.24) | (288.80) | (317.85) | (149.40) | (45.22) |
EBIT |
(50.04) | (117.28) | (86.69) | (89.31) | (191.88) | (288.53) | (301.02) | (322.72) | (150.42) | (45.89) |
Income from Continuous Operations |
(58.07) | (120.87) | (86.42) | (76.97) | (189.29) | (290.02) | (293.65) | (322.97) | (153.10) | (58.20) |
Income from Discontinued Operations |
— | — | — | — | — | — | — | 38.74 | 105.52 | 241.66 |
Consolidated Net Income/Loss |
(58.07) | (120.87) | (86.42) | (76.97) | (189.29) | (290.02) | (293.65) | (284.23) | (47.58) | 183.45 |
EPS (Basic, from Continuous Ops) |
(23.14) | (41.40) | (25.70) | (22.21) | (52.67) | (78.51) | (78.45) | (83.00) | (38.26) | (14.40) |
EPS (Basic, from Discontinued Ops) |
— | — | — | — | — | — | — | 10.00 | 26.37 | 59.77 |
EPS (Basic, Consolidated) |
(23.14) | (41.40) | (25.70) | (22.21) | (52.67) | (78.51) | (78.45) | (73.03) | (11.89) | 45.38 |
EPS (Diluted, from Cont. Ops) |
(23.14) | (41.40) | (25.70) | (22.21) | (52.67) | (78.51) | (78.45) | (83.00) | (38.26) | (14.40) |
EPS (Diluted, from Disc. Ops) |
— | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 |
Shares (Diluted, Average) |
2.51 | 2.92 | 3.36 | 3.47 | 3.59 | 3.69 | 3.74 | 3.89 | 4.00 | 4.04 |
EPS (Diluted, Consolidated) |
(23.14) | (41.40) | (25.70) | (22.21) | (52.67) | (78.51) | (78.45) | (73.03) | (11.89) | 45.38 |
EBITDA Margin |
(22.53%) | (83.47%) | (37.65%) | (27.88%) | (96.26%) | (115.27%) | (205.21%) | (679.13%) | (504.39%) | (702.16%) |
Operating Cash Flow Margin |
3.88% | (50.77%) | (35.76%) | (30.68%) | 46.28% | (34.95%) | (103.69%) | (673.08%) | (465.88%) | (74.13%) |
In millions of $ except per-share values · columns are period end dates · fundamentals updated 25 Oct 2026